Amicus Therapeutics (FOLD) Tops Q1 EPS by 5c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
May 1, 2025 7:00 AM EDT1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER
Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S.
Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand
Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H
Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER
Reiterating GAAP Profitability During H2... More
